Neurocrine Biosciences, Inc. announced new data from the Phase 4 KINECT-PRO open-label study, demonstrating robust and sustained improvements in physical, social, and emotional functioning in patients with tardive dyskinesia (TD) taking once-daily INGREZZA capsules. These results were presented at 2025 Psych Congress Elevate.
KINECT-PRO is the first and only study to specifically evaluate and demonstrate patient-reported improvement with vesicular monoamine transporter 2 inhibitor treatment, specifically INGREZZA, on TD using multiple clinically validated scales. Improvements were observed as early as Week 4 after initial treatment with the lowest clinically effective INGREZZA dose (40 mg) and sustained through Week 24.
Robust and sustained improvements were seen in physical, social, and emotional functioning, along with a substantial reduction in TD severity, regardless of baseline TD severity or underlying psychiatric condition. Even patients with milder TD movements experienced impact at baseline and saw improvements by Week 24, reinforcing INGREZZA's value in managing this challenging condition.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.